KCTBASE

Bowel Perforation after Erlotinib Treatment in a Patient with Non-Small Cell Lung Cancer

Yonsei Medical Journal 2011년 52권 4호 p.695 ~ p.698

천윤홍(Cheon Yun-Hong) - Gyeongsang National University School of Medicine Department of Internal Medicine
김문진(Kim Moon-Jin) - Gyeongsang National University School of Medicine Department of Internal Medicine
강민규(Kang Min-Gyu) - Gyeongsang National University School of Medicine Department of Internal Medicine
김희진(Kim Hee-Jin) - Gyeongsang National University School of Medicine Department of Internal Medicine
이상수(Lee Sang-Su) - Gyeongsang National University School of Medicine Department of Internal Medicine
김차영(Kim Cha-Young) - Gyeongsang National University School of Medicine Department of Internal Medicine
전대홍(Jeon Dae-Hong) - Gyeongsang National University School of Medicine Department of Internal Medicine
김유은(Kim Yu-Eun) - Gyeongsang National University School of Medicine Department of Internal Medicine
이경원(Lee Gyeong-Won) - Gyeongsang National University School of Medicine Department of Internal Medicine

Abstract

Erlotinib is accepted as a standard second-line chemotherapeutic agent in patients with non-small cell lung cancer who are refractory or resistant to first-line platinum-based chemotherapy. There has been no previous report of bowel perforation with or without gastrointestinal metastases related to erlotinib in patients with non-small cell lung cancer. The exact mechanism of bowel perforation in patients who received erlotinib remains unclear. In this report, we report the first case of enterocutaneous fistula in a female patient with metastatic non-small cell lung cancer 9 months, following medication with erlotinib as second-line chemotherapy.